Andrew Huberman· PhD
This one has heavy RCT support and Lilly has the patent so pretty sure it meets the bar for clinically effective.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
This one has heavy RCT support and Lilly has the patent so pretty sure it meets the bar for clinically effective.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the data from the semaglutide the OIC trial came out last year and as expected reduced the rate of heart attacks Strokes all cause mortality according to cardiac uh uh for for cardiac reasons
for people with type 2 diabetes for smagletite and it does reduce all-cause mortality in meta-analyses of randomized controlled trials